vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Stock Yards Bancorp, Inc. (SYBT). Click either name above to swap in a different company.

Stock Yards Bancorp, Inc. is the larger business by last-quarter revenue ($104.4M vs $75.1M, roughly 1.4× MEDIFAST INC). On growth, Stock Yards Bancorp, Inc. posted the faster year-over-year revenue change (11.7% vs -36.9%). Stock Yards Bancorp, Inc. produced more free cash flow last quarter ($154.0M vs $-6.6M). Over the past eight quarters, Stock Yards Bancorp, Inc.'s revenue compounded faster (11.9% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Community Trust Bancorp is an American regional bank holding company that was founded in 1903 as Pikeville National Bank. The renamed corporation continues to have its headquarters in Pikeville, Kentucky, at the heart of Appalachia. Community Trust Bancorp operates a commercial bank, Community Trust Bank, and a trust company, Community Trust and Investment Company of Lexington.

MED vs SYBT — Head-to-Head

Bigger by revenue
SYBT
SYBT
1.4× larger
SYBT
$104.4M
$75.1M
MED
Growing faster (revenue YoY)
SYBT
SYBT
+48.6% gap
SYBT
11.7%
-36.9%
MED
More free cash flow
SYBT
SYBT
$160.6M more FCF
SYBT
$154.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
SYBT
SYBT
Annualised
SYBT
11.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
SYBT
SYBT
Revenue
$75.1M
$104.4M
Net Profit
$36.6M
Gross Margin
69.4%
Operating Margin
-10.4%
45.9%
Net Margin
35.1%
Revenue YoY
-36.9%
11.7%
Net Profit YoY
15.5%
EPS (diluted)
$-1.64
$1.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SYBT
SYBT
Q4 25
$75.1M
$104.4M
Q3 25
$89.4M
$101.5M
Q2 25
$105.6M
$97.8M
Q1 25
$115.7M
$93.5M
Q4 24
$119.0M
$93.5M
Q3 24
$140.2M
$89.8M
Q2 24
$168.6M
$85.7M
Q1 24
$174.7M
$83.3M
Net Profit
MED
MED
SYBT
SYBT
Q4 25
$36.6M
Q3 25
$-2.3M
$36.2M
Q2 25
$2.5M
$34.0M
Q1 25
$-772.0K
$33.3M
Q4 24
$31.7M
Q3 24
$1.1M
$29.4M
Q2 24
$-8.2M
$27.6M
Q1 24
$8.3M
$25.9M
Gross Margin
MED
MED
SYBT
SYBT
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
SYBT
SYBT
Q4 25
-10.4%
45.9%
Q3 25
-4.6%
45.0%
Q2 25
-1.0%
43.9%
Q1 25
-1.1%
44.5%
Q4 24
0.6%
41.9%
Q3 24
1.5%
41.2%
Q2 24
-4.7%
41.2%
Q1 24
4.5%
39.5%
Net Margin
MED
MED
SYBT
SYBT
Q4 25
35.1%
Q3 25
-2.5%
35.7%
Q2 25
2.3%
34.8%
Q1 25
-0.7%
35.6%
Q4 24
33.9%
Q3 24
0.8%
32.7%
Q2 24
-4.8%
32.2%
Q1 24
4.8%
31.1%
EPS (diluted)
MED
MED
SYBT
SYBT
Q4 25
$-1.64
$1.24
Q3 25
$-0.21
$1.23
Q2 25
$0.22
$1.15
Q1 25
$-0.07
$1.13
Q4 24
$0.08
$1.07
Q3 24
$0.10
$1.00
Q2 24
$-0.75
$0.94
Q1 24
$0.76
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SYBT
SYBT
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$26.8M
Stockholders' EquityBook value
$198.9M
$1.1B
Total Assets
$248.0M
$9.5B
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SYBT
SYBT
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Total Debt
MED
MED
SYBT
SYBT
Q4 25
$26.8M
Q3 25
$26.8M
Q2 25
Q1 25
$26.8M
Q4 24
$26.8M
Q3 24
$26.8M
Q2 24
$26.8M
Q1 24
$26.8M
Stockholders' Equity
MED
MED
SYBT
SYBT
Q4 25
$198.9M
$1.1B
Q3 25
$214.7M
$1.0B
Q2 25
$216.0M
$1.0B
Q1 25
$211.0M
$975.5M
Q4 24
$210.1M
$940.5M
Q3 24
$207.3M
$934.1M
Q2 24
$205.3M
$894.5M
Q1 24
$211.0M
$874.7M
Total Assets
MED
MED
SYBT
SYBT
Q4 25
$248.0M
$9.5B
Q3 25
$268.2M
$9.3B
Q2 25
$269.3M
$9.2B
Q1 25
$280.0M
$9.0B
Q4 24
$284.2M
$8.9B
Q3 24
$291.2M
$8.4B
Q2 24
$293.5M
$8.3B
Q1 24
$302.8M
$8.1B
Debt / Equity
MED
MED
SYBT
SYBT
Q4 25
0.02×
Q3 25
0.03×
Q2 25
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.03×
Q2 24
0.03×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SYBT
SYBT
Operating Cash FlowLast quarter
$-5.3M
$166.0M
Free Cash FlowOCF − Capex
$-6.6M
$154.0M
FCF MarginFCF / Revenue
-8.8%
147.5%
Capex IntensityCapex / Revenue
1.8%
11.5%
Cash ConversionOCF / Net Profit
4.54×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$260.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SYBT
SYBT
Q4 25
$-5.3M
$166.0M
Q3 25
$12.1M
$38.2M
Q2 25
$-3.4M
$55.9M
Q1 25
$3.4M
$19.8M
Q4 24
$-4.9M
$142.9M
Q3 24
$9.1M
$55.4M
Q2 24
$13.1M
$51.1M
Q1 24
$7.3M
$17.4M
Free Cash Flow
MED
MED
SYBT
SYBT
Q4 25
$-6.6M
$154.0M
Q3 25
$10.8M
$35.2M
Q2 25
$-4.8M
$53.5M
Q1 25
$1.9M
$17.8M
Q4 24
$-7.2M
$133.0M
Q3 24
$7.7M
$53.9M
Q2 24
$11.1M
$47.9M
Q1 24
$5.4M
$15.6M
FCF Margin
MED
MED
SYBT
SYBT
Q4 25
-8.8%
147.5%
Q3 25
12.0%
34.6%
Q2 25
-4.5%
54.7%
Q1 25
1.6%
19.1%
Q4 24
-6.1%
142.3%
Q3 24
5.5%
60.0%
Q2 24
6.6%
55.9%
Q1 24
3.1%
18.7%
Capex Intensity
MED
MED
SYBT
SYBT
Q4 25
1.8%
11.5%
Q3 25
1.5%
3.0%
Q2 25
1.3%
2.5%
Q1 25
1.3%
2.1%
Q4 24
1.9%
10.5%
Q3 24
1.0%
1.7%
Q2 24
1.1%
3.8%
Q1 24
1.1%
2.2%
Cash Conversion
MED
MED
SYBT
SYBT
Q4 25
4.54×
Q3 25
1.05×
Q2 25
-1.36×
1.64×
Q1 25
0.59×
Q4 24
4.51×
Q3 24
8.04×
1.89×
Q2 24
1.85×
Q1 24
0.88×
0.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons